Background & aim: Dyslipidemia, characterized by hyper-cholesterolemia and hypertriglyceridemia, is a central component of metabolic dysfunction-associated steatohepatitis (MASH) pathogenesis. While being highly instrumental in drug development, preclinical models of MASH often fail to recapitulate a human-like lipoprotein profile. To enhance…
Background & aim: Histopathological fibrosis staging is a key endpoint in preclinical drug development for MASH. However, the MASH CRN (Kleiner) system assigns one global stage per biopsy, potentially obscuring subtle treatment-related collagen remodelling and tissue heterogeneity. We developed an…
Background & aim: Menopause is associated with significant health changes and a broad range of symptoms, including adverse changes in body composition and metabolism and an increased risk of osteoporosis. Estradiol (E2)-based hormone replacement therapy effectively alleviates several menopausal symptoms…
Background & aim: The long-acting glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide was recently approved as the first GLP-1–based therapy for people with MASH and moderate-to-severe fibrosis. Clinical studies have demonstrated that semaglutide not only improves liver histology but also reverses…
Background & aim: Aims: Survodutide is a novel long-acting dual glucagon (GCGR)/glucagon-like peptide-1 (GLP-1R) receptor agonist currently in phase-3 clinical development for the treatment of people living with obesity and metabolic dysfunction-associated steatohepatitis. Emerging evidence suggests impaired renal GCGR function…
Background & aim: Conventional methods for assessing skeletal muscle remodelling, including lean mass, muscle weight, and histology, lack the spatial resolution and sensitivity to capture three-dimensional muscle architecture. Here, we developed a scalable, non-destructive, AI-enabled light-sheet fluorescence microscopy (LSFM) platform…
Background & aim: Psychiatric compounds modulate complex brain networks, making whole-brain assessment of neuronal activity essential for understanding their mechanisms of action. Activity-dependent genes such as c-Fos, and other stimulus-regulated genes (SRGs) provide complementary molecular readouts of neuronal activation, and…
Background & aim: Two-dimensional (2D) histopathology is the current gold-standard for assessing toxicology in ovaries. However, it can be a time-consuming process limited by section-to section variability, subjective interpretation and sampling bias. To overcome these limitations, we have developed a…
Background & aim: Efficient delivery of anti-β-amyloid (Aβ) antibodies across the blood–brain barrier (BBB) remains a central challenge in Alzheimer’s disease (AD) therapy. Therapeutic Aβ-targeted antibodies engineered for receptor-mediated transcytosis display improved brain exposure and therapeutic efficacy, yet their brain-wide…
